UCB Unveils Positive Findings from GEMZ Phase 3 Study on Fenfluramine for Seizures UCB revealed promising results from its GEMZ Phase 3 study, showing fenfluramine effectively reduces seizure frequency in patients with CDKL5 Deficiency Disorder.

UCB Unveils Positive Findings from GEMZ Phase 3 Study on Fenfluramine for Seizures #USA #Atlanta #fenfluramine #CDKL5_Deficiency #GEMZ_Study